Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin

E. P. Balaban, R. G. Sheehan, P. E. Lipsky, E. P. Frenkel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We administered antithymocyte globulin to a 52-year-old man with cutaneous sclerosis (scleroderma) and severe aplastic anemia for treatment of the aplastic lesion. The use of this therapy resulted not only in marrow recovery but also in resolution of the sclerosis. This observation indicates that T lymphocytes, their products, or both, are important factors in the pathogenesis of cutaneous sclerosis. Furthermore, the success of this treatment could play a role in future investigations involving the treatment of scleroderma and scleroderma-like conditions.

Original languageEnglish (US)
Pages (from-to)56-58
Number of pages3
JournalAnnals of Internal Medicine
Volume106
Issue number1
StatePublished - 1987

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Sclerosis
Skin
Therapeutics
Bone Marrow
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Balaban, E. P., Sheehan, R. G., Lipsky, P. E., & Frenkel, E. P. (1987). Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. Annals of Internal Medicine, 106(1), 56-58.

Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. / Balaban, E. P.; Sheehan, R. G.; Lipsky, P. E.; Frenkel, E. P.

In: Annals of Internal Medicine, Vol. 106, No. 1, 1987, p. 56-58.

Research output: Contribution to journalArticle

Balaban, EP, Sheehan, RG, Lipsky, PE & Frenkel, EP 1987, 'Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin', Annals of Internal Medicine, vol. 106, no. 1, pp. 56-58.
Balaban, E. P. ; Sheehan, R. G. ; Lipsky, P. E. ; Frenkel, E. P. / Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. In: Annals of Internal Medicine. 1987 ; Vol. 106, No. 1. pp. 56-58.
@article{035a603fcb1c4a3d8b156a9ea693b982,
title = "Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin",
abstract = "We administered antithymocyte globulin to a 52-year-old man with cutaneous sclerosis (scleroderma) and severe aplastic anemia for treatment of the aplastic lesion. The use of this therapy resulted not only in marrow recovery but also in resolution of the sclerosis. This observation indicates that T lymphocytes, their products, or both, are important factors in the pathogenesis of cutaneous sclerosis. Furthermore, the success of this treatment could play a role in future investigations involving the treatment of scleroderma and scleroderma-like conditions.",
author = "Balaban, {E. P.} and Sheehan, {R. G.} and Lipsky, {P. E.} and Frenkel, {E. P.}",
year = "1987",
language = "English (US)",
volume = "106",
pages = "56--58",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin

AU - Balaban, E. P.

AU - Sheehan, R. G.

AU - Lipsky, P. E.

AU - Frenkel, E. P.

PY - 1987

Y1 - 1987

N2 - We administered antithymocyte globulin to a 52-year-old man with cutaneous sclerosis (scleroderma) and severe aplastic anemia for treatment of the aplastic lesion. The use of this therapy resulted not only in marrow recovery but also in resolution of the sclerosis. This observation indicates that T lymphocytes, their products, or both, are important factors in the pathogenesis of cutaneous sclerosis. Furthermore, the success of this treatment could play a role in future investigations involving the treatment of scleroderma and scleroderma-like conditions.

AB - We administered antithymocyte globulin to a 52-year-old man with cutaneous sclerosis (scleroderma) and severe aplastic anemia for treatment of the aplastic lesion. The use of this therapy resulted not only in marrow recovery but also in resolution of the sclerosis. This observation indicates that T lymphocytes, their products, or both, are important factors in the pathogenesis of cutaneous sclerosis. Furthermore, the success of this treatment could play a role in future investigations involving the treatment of scleroderma and scleroderma-like conditions.

UR - http://www.scopus.com/inward/record.url?scp=0023133713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023133713&partnerID=8YFLogxK

M3 - Article

C2 - 3491559

AN - SCOPUS:0023133713

VL - 106

SP - 56

EP - 58

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -